Search Results for "activate"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for activate. Results 311 to 320 of 1332 total matches.

Gabapentin - A New Anticonvulsant

   
The Medical Letter on Drugs and Therapeutics • Apr 29, 1994  (Issue 921)
with antiepileptic activity are generally tried first for this indication. PREVIOUSLY AVAILABLE DRUGS ...
Gabapentin (Neurontin - Parke-Davis), a cyclohexane acetic acid derivative, has been approved by the US Food and Drug Administration for use in addition to other antiepileptic drugs in patients with partial (focal) seizures with or without secondary generalization. Since this diagnostic category includes the largest number of patients with intractable epilepsy, new drugs with antiepileptic activity are generally tried first for this indication.
Med Lett Drugs Ther. 1994 Apr 29;36(921):39-40 |  Show IntroductionHide Introduction

Treatment of Hypothermia

   
The Medical Letter on Drugs and Therapeutics • Dec 23, 1994  (Issue 938)
. Hypothermia associated with exhaustion during outdoor sports activities can occur even at relatively mild ...
This winter physicians in many area may see patients suffering from hypothermia. Old age, lack of adequate housing, drug overdose and alcohol ingestion are often prediposing factors, but hypothermia also occurs in healthy young people after prolonged exposure to cold due to incapacitating trauma or cold water immersion. Hypothermia associated with exhaustionduring outdoor sports activities can occur even at relatively mild temperatures.
Med Lett Drugs Ther. 1994 Dec 23;36(938):116-7 |  Show IntroductionHide Introduction

Two New Retinoids for Psoriasis

   
The Medical Letter on Drugs and Therapeutics • Nov 07, 1997  (Issue 1013)
), an acetylenic retinoid prodrug, is rapidly converted to its active form, tazarotenic acid. Both compounds appear ...
The US Food and Drug Administration (FDA) has approved two new retinoids for treatment of psoriasis. Tazarotene gel 0.05% and 0.1% (Tazorac - Allergan) is being marketed for topical use in patients with stable, mild to moderate plaque psoriasis. Acitretin (Soriatane - Roche) is being promoted for systemic use in severe psoriasis.
Med Lett Drugs Ther. 1997 Nov 7;39(1013):105-6 |  Show IntroductionHide Introduction

Celecoxib for Arthritis

   
The Medical Letter on Drugs and Therapeutics • Jan 29, 1999  (Issue 1045)
inhibits the activity of CYP2D6 and therefore might increase serum concentrations of drugs metabolized ...
Celecoxib, a selective COX-2 inhibitor, has been approved by the FDA for treatment of osteoarthritis and rheumatoid arthritis.
Med Lett Drugs Ther. 1999 Jan 29;41(1045):11-2 |  Show IntroductionHide Introduction

Novoseven for Non-Hemophilia Hemostasis

   
The Medical Letter on Drugs and Therapeutics • Apr 26, 2004  (Issue 1181)
NOVOSEVEN FOR NON-HEMOPHILIA HEMOSTASIS Recombinant activated coagulation factor Vll (rFVIIa ...
Recombinant activated coagulation factor Vll (rFVIIa; NovoSeven - Novo Nordisk), which is marketed worldwide for treatment of bleeding episodes in hemophilia patients with inhibitors to factor VIII or IX, is now being used off-label to stop bleeding in patients who do not have hemophilia. An article in the lay press reported that one or two doses has stopped previously uncontrollable bleeding due to gunshot wounds (B Wysocki, Jr, Wall St Journal, March 17, 2004, page B1).
Med Lett Drugs Ther. 2004 Apr 26;46(1181):33-4 |  Show IntroductionHide Introduction

Prothrombin Complex Concentrates to Reverse Warfarin-Related Bleeding

   
The Medical Letter on Drugs and Therapeutics • Oct 03, 2011  (Issue 1374)
units/mL INR ...
Warfarin-related bleeding, especially intracranial hemorrhage, can be catastrophic. Several products are available to reverse warfarin’s anticoagulant effect.
Med Lett Drugs Ther. 2011 Oct 3;53(1374):78-9 |  Show IntroductionHide Introduction

Macitentan (Opsumit) for Pulmonary Arterial Hypertension

   
The Medical Letter on Drugs and Therapeutics • Feb 17, 2014  (Issue 1436)
or to 3 mg or 10 mg of the active drug once daily. The composite primary endpoint was time ...
The FDA has approved macitentan (ma" si ten' tan; Opsumit – Actelion), for oral treatment of pulmonary arterial hypertension (PAH). Macitentan is the second nonselective endothelin receptor antagonist approved for PAH. It is a derivative of bosentan (Tracleer), which is also manufactured by Actelion, and is scheduled to become available generically in 2015. Riociguat (Adempas), another new drug for this indication, will be reviewed in a future issue. Volibris
Med Lett Drugs Ther. 2014 Feb 17;56(1436):15-6 |  Show IntroductionHide Introduction

AspireAssist - A New Device for Weight Loss

   
The Medical Letter on Drugs and Therapeutics • Aug 29, 2016  (Issue 1502)
), available only as an abstract, 171 patients were randomized in a 2:1 ratio to active treatment ...
The FDA has approved AspireAssist (Aspire Bariatrics), a weight-loss device that permits patients to drain a portion of their stomach contents through a gastrostomy tube into a toilet after each meal. It is approved for long-term use in combination with lifestyle modifications in adults ≥22 years old who have a body mass index (BMI) of 35 to 55 and have not been able to achieve and maintain weight loss with nonsurgical therapy.
Med Lett Drugs Ther. 2016 Aug 29;58(1502):109-10 |  Show IntroductionHide Introduction

An Oral Cholera Vaccine for Travelers (Vaxchora)

   
The Medical Letter on Drugs and Therapeutics • Aug 29, 2016  (Issue 1502)
during vaginal delivery. DRUG INTERACTIONS — Antibiotics may be active against the vaccine strain ...
The FDA has approved Vaxchora (PaxVax), a single-dose, oral, live-attenuated cholera vaccine, to protect against disease caused by Vibrio cholerae serogroup O1 in adults 18-64 years old traveling to cholera-affected areas. Vaxchora is the only cholera vaccine available in the US. A whole-cell killed injectable vaccine was previously approved, but is no longer available in the US.
Med Lett Drugs Ther. 2016 Aug 29;58(1502):113-4 |  Show IntroductionHide Introduction

Exablate Neuro for Essential Tremor

   
The Medical Letter on Drugs and Therapeutics • Mar 27, 2017  (Issue 1517)
of everyday activities difficult. The most effective drugs used to treat essential tremor are the beta ...
The FDA has approved use of Exablate Neuro (Insightec) for unilateral thalamotomy to treat medication-refractory essential tremor in patients ≥22 years old. Exablate Neuro uses magnetic resonance-guided focused ultrasound (MRgFUS) to create lesions in the ventral intermediate nucleus of the thalamus. MRgFUS is also approved in the US for treatment of uterine fibroids and for pain palliation of bone metastases.
Med Lett Drugs Ther. 2017 Mar 27;59(1517):52-3 |  Show IntroductionHide Introduction